Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

The Role of Surgery for the Treatment of Upper Esophageal Cancer

상부 식도암에서 수술적 치료의 유용성

  • Park, Jae-Kil (Department of Thoracic and Cardiovascular Surgery, St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Sa, Young-Jo (Department of Thoracic and Cardiovascular Surgery, St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Nam, Sang-Yong (Department of Thoracic and Cardiovascular Surgery, St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Park, Kuhn (Department of Thoracic and Cardiovascular Surgery, Daejeon St. Mary's Hospital, The Catholic University of Korea College of Medicine)
  • 박재길 (가톨릭대학교 의과대학 성모병원 흉부외과학교실) ;
  • 사영조 (가톨릭대학교 의과대학 성모병원 흉부외과학교실) ;
  • 남상용 (가톨릭대학교 의과대학 성모병원 흉부외과학교실) ;
  • 박건 (가톨릭대학교 의과대학 대전성모병원 흉부외과학교실)
  • Published : 2007.10.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In the past, radiotherapy was the gold standard for the treatment of upper esophageal cancer, but the long-term follow-up was disappointing. There is still ongoing debate on the surgical management of these patients. This study was undertaker to update our experience with upper esophageal carcinoma and to evaluate the effectiveness of surgery. Material and Method: From May 1995 to December 2005, 147 patients with esophageal cancer underwent surgery at our hospital. They were divided into two groups: one group consisted of 23 patients with upper esophageal (cervical and upper thoracic) cancer and another group consisted of 424 patients with lower esophageal (middle thoracic, lower thoracic and abdominal) cancer. We evaluated the effectiveness of surgical treatment between the 2 groups by measuring the rate of complete surgical resection, the postoperative complications, the postoperative mortality, tumor recurrence, the average life expectancy and the long-term survival. Result: On comparing both groups, there was no significant difference in the distribution of the pathological stage and no significant difference in the percentage of performing complete surgical resection. The percentage of post-operative complications was 39.1% (9 out of 23 patients) in the upper esophageal cancer group, and this was significantly higher than 16.9% (21 out of 124 patients) in the lower esophageal cancer group (p<0.05). However, there was no significant statistical difference between the groups for the percentages of postoperative mortality, tumor recurrence or the postoperative average life expectancy. Conclusion: There was no significant difference in operative mortality or surgical effectiveness between the 2 groups. Therefore, we thought that surgical treatment is also effective for treating upper esophageal cancer, but further investigation with large patient populations will be required.

배경: 상부 식도암에 대한 종래의 표준적 치료는 방사선 조사였으나 결과는 만족스럽지 않았으며, 아직도 수술적 치료를 적용하는 데에는 의견의 차이가 있다. 저자들은 상부식도암에 대하여 수술적 치료를 적극적으로 시행하여 왔으며, 그의 효과를 분석해 보고자 하였다. 대상 및 방법: 1995년부터 2005년까지 저자들이 수술을 시행한 식도암 증례는 모두 147예였으며, 이들을 상부 식도암(경부 및 상흉부 식도암) 23예와 하부 식도암(중, 하흉부 및 복부 식도암) 124예의 2군으로 구분하여, 수술의 완전 절제율과 수술의 합병증 및 사망률, 재발률,그리고 생존율 등을 비교함으로써 양군에서의 수술의 유용성을 비교해 보았다. 결과: 양 군 간에 병기 분포는 유사하였으며, 완전 절제율에서도 유의한 차이를 발견할 수 없었다. 수술의 합병증 발생률은 상부 식도암군에서 유의하게 높았으나(39.1% vs 16.9%, p<0.05), 수술 사망률이나 재발률 및 장기 생존율에서의 차이는 없었다. 결론: 양 군 간에 수술 사망률이나 수술의 효과 면에서 차이가 없어 상부 식도암에서도 수술적 치료는 유용하다고 판단되었으나, 향후 보다 많은 증례의 분석이 필요할 것이라고 생각한다.

Keywords

References

  1. Kelly DJ, Wolf R, Shaha AR, et al. Impact of clinicopathologic parameters on patient survival in carcinoma of the cervical esophagus. Am J Surg 1995;170:427-31 https://doi.org/10.1016/S0002-9610(99)80322-5
  2. Triboulet JP, Mariette C, Chevalier D, Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus. Arch Surg 2001;136:1164-70 https://doi.org/10.1001/archsurg.136.10.1164
  3. Dimick JB, Cattaneo SM, Lipsett PA, Pronovost PJ, Heitmiller RF. Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg 2001;72:334-41 https://doi.org/10.1016/S0003-4975(01)02781-3
  4. Metzger R, Bollschweiler E, Vallbohmer D, Maish M, DeMeester TR, Holscher AH. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus 2004;17:310-4 https://doi.org/10.1111/j.1442-2050.2004.00431.x
  5. Roka R, Kriwanek S, Roka S. Therapy of cervical esophageal carcinoma. Recent results in cancer research, vol 155, Berlin: Springer-Verlag. 2000
  6. Urba S, Forastiere A, Wolf G, et al. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. J Clin Oncol 1994;12:946-53 https://doi.org/10.1200/JCO.1994.12.5.946
  7. Coia L, Engstrom P, Paul R, Stafford P, Hanks G. Long-term resultd of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991;20:29-36 https://doi.org/10.1016/0360-3016(91)90134-P
  8. Leichman L, Steiger A, Seydel H, et al. Preoperative chemotherapy plus radiation therapy for patients with cancer of the esophagus: potentially curative approach. J Clin Oncol 1984;2:75-9 https://doi.org/10.1200/JCO.1984.2.2.75
  9. Zhang X, Watson DI, Jamieson GG, Bessell JR, Devitt PG. Neoadjuvant chemoradiotherapy for esophageal carcinoma. Dis Esophagus 2005;18:104-8 https://doi.org/10.1111/j.1442-2050.2005.00461.x
  10. Terrosu G, Cedolini C, Bresadola V, et al. Preoperative chemoradiotherapy in cancer of the thoracic esophagus. Dis Esophagus 2003;16:9-16 https://doi.org/10.1046/j.1442-2050.2003.00280.x
  11. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005;137:172-9 https://doi.org/10.1016/j.surg.2004.06.033
  12. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88:338-56 https://doi.org/10.1046/j.1365-2168.2001.01670.x
  13. Mendenhall W, Pearson J, Vogel S, et al. Carcinoma of the cervical esophagus treated with radiation therapy. Laryngoscope 1988;98:769-71
  14. Harrison D, Thompson A. Pharyngolaryngoesophagectomy with pharyngogastric anastomosis for cancer of the hypopharynx: review of 101 operations. Head Neck Surg 1986;8:418-28 https://doi.org/10.1002/hed.2890080605
  15. Urschel JD, Ashiku S, Thurer R, Sellke FW. Salvage or planned esophagectomy after chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus 2003;16:60-5 https://doi.org/10.1046/j.1442-2050.2003.00296.x
  16. Wei W, Lam L, Yuen P, Wong J. Current status of pharyngolaryngo-esophagectomy and pharyngogastric anastomosis. Head Neck 1998;20:240-4 https://doi.org/10.1002/(SICI)1097-0347(199805)20:3<240::AID-HED9>3.0.CO;2-0
  17. Peracchia A, Bonavina L, Botturi M, Pagani M, Via A, Saino G. Current status of surgery for carcinoma of the hypopharynx and cervical esophagus. Dis Esophagus 2001;14:95-7 https://doi.org/10.1046/j.1442-2050.2001.00163.x
  18. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006;19:425-32 https://doi.org/10.1111/j.1442-2050.2006.00622.x